# John Sweetenham
ထိပ်တန်း Podcast တခုကိုဖြစ်စဉ်များ
နောက်ဆုံးပေါ်:
Top podcast episodes featuring john sweetenham.
Day 4: Top Takeaways From ASCO24
Dr. John Sweetenham shares highlights from Day 4 of the 2024 ASCO Annual Meeting, including exciting new data from the IMROZ trial in multiple myeloma, adjuvant therapy for triple-negative breast cancer in A-BRAVE, and the front-line treatment of advanced renal cell carcinoma in JAVELIN Renal-101. …
Day 3: Top Takeaways From ASCO24
Dr. John Sweetenham shares highlights from Day 3 of the 2024 ASCO Annual Meeting, including selected studies on the treatment of cancer cachexia, surgical approaches in advanced ovarian cancer, and advanced colorectal cancer with liver metastases.
TRANSCRIPT
Dr. John Sweetenham: I'm Dr. John Swe…
Day 2: Top Takeaways From ASCO24
Dr. John Sweetenham shares highlights from Day 2 of the 2024 ASCO Annual Meeting, including potentially practice-changing results in advanced Hodgkin lymphoma, intriguing data on the effect of metformin on active surveillance for prostate cancer, and the potential of AI to improve patient outreach …
Day 1: Top Takeaways From ASCO24
In the first episode of a special daily series during the 2024 ASCO Annual Meeting, Dr. John Sweetenham shares highlights from Day 1, including exciting data on the CROWN trial in NSCLC, the ASC4First study in chronic myeloid leukemia, and the effects of high-deductible health plans on cancer survi…
Novel Approaches in Hematologic Malignancies at ASCO24
Dr. John Sweetenham and Dr. Marc Braunstein look ahead at key abstracts across the spectrum of hematologic malignancies that will be presented at the 2024 ASCO Annual Meeting, including the OPTIC trial in chronic myeloid leukemia, treatment options for transplant-ineligible patients with multiple m…
Innovations in CAR T-Cell Therapy for Multiple Myeloma
Drs. John Sweetenham and Shaji Kumar discuss the emergence of CAR T-cell therapy for multiple myeloma, its benefits and challenges for patients, and its potential role earlier in the treatment of disease.
TRANSCRIPT
Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from the UT Southwestern Ha…
What the FDA CAR T-Cell Therapy Investigation Means for Oncologists
Drs. John Sweetenham and Fred Locke discuss the FDA investigation on the risk of cancer from CAR T-cell therapy and share insights on the known number of cases and the potential implications on clinical research and patient care.
TRANSCRIPT
Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham fr…
Managing the Complexities of Oncology Practice in 2024
Drs. John Sweetenham and Lawrence Shulman discuss the challenges that oncologists will be confronting in 2024 and share insights on how to build clinician resilience and optimize the oncology workforce to provide better, safer care for patients with cancer.
TRANSCRIPT
Dr. John Sweetenham: Hell…
Highlights in Hematologic Malignancies at ASCO23
Drs. John Sweetenham and Marc Braunstein discuss advances in hematologic malignancies featured at the 2023 ASCO Annual Meeting, including the potentially practice-changing SWOG-S1826 study in Hodgkin lymphoma, the promise of bispecific antibodies in B-cell malignancies, and a novel approach to deli…
ASCO23: COMMANDS, CAPTIVATE, and Key Studies in Hematologic Malignancies
Dr. John Sweetenham and Dr. Marc Braunstein discuss the role of maintenance therapy in high-risk multiple myeloma, advances in myelodysplastic syndromes in the COMMANDS study, the promise of bispecific antibodies in the pivotal EPCORE NHL-1 in relapsed/refractory large B-cell lymphoma, and improvi…
PODCAST ရှာဖွေရေးအင်ဂျင်
3,834,647ပေါ့တ်ကာစ်များနှင့်197,305,122အပိုင်းများကို လူများ၊ နေရာများ သို့မဟုတ် အကြောင်းအရာများအလိုက် ရှာဖွေရန် ကျွန်ုပ်တို့၏ဝဘ်ဆိုက်ကို အသုံးပြုနိုင်ပါသည်။
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
ပြင်ဆင်ပါ
ပေါ့ဒ်ကတ်စ် ဒေတာဘေ့စ်ကို နောက်ဆုံးပေါ်အချိန်နှင့်တပြေးညီဖြစ်စေရန် ကူညီပေးသည့်အတွက် ကျေးဇူးတင်ပါသည်။
